VP, Clinical Product Strategy at Hyro · CCO of HIFP (adopted by non-dissent 2026-09-07, modifiable) · Concept originator + Ethical Framework author
Ask: Timeline for reaching Karen with the briefing document (HIFP-general-counsel-briefing-v0.1) + your intuition on whether she'll engage as a paid consultant, an advisor slot, or purely a favor/mentor. She's the load-bearing pre-external gate — blocks Ledger §3.24 + everything downstream (NDA template · IP counsel referrals · delete-forever design · Coverage Navigator pressure-test).
Why: Nothing in the v4 kit can be distributed externally until Karen has read it and pressure-tested the regulatory + IP posture. This is the tallest gate we're looking at.
Ref: Ledger §3.24 · GC Briefing v0.1
Ask: Full v0.1 expansion of the three commitments (User Primacy · Boundary Integrity · Transparency with Agency). Skeleton adopted at Monday alignment; v0.1 needs to expand each commitment with (a) operational mechanics, (b) testing protocol, (c) governance review cadence. Anchor to Sandel / Harvard Justice course as referenced in Appendix.
Why: POV v4 §1 elevates User Primacy to mission-level; §8 references all three commitments; Ethical Framework becomes the through-line document above Advice-Boundary + Model-Fairness + Data-Lifecycle + Life-Insurance-Judo memos. It's the "what does HIFP promise to be" document.
Ref: Ledger §3.17 · POV v4 §1 + §8 + Appendix B
Ask: Confirm CCO (adopted by non-dissent 2026-09-07) OR name preferred alternative. Options discussed: CMO · COO · CCO · President · COFO (Chief Operating and Financial Officer, your on-transcript alt-framing). Once locked, this propagates across POV v4, Investor Deck v4, Team page, GC Brief, LinkedIn cues for external distribution.
Why: Team-section polish across all v4 artifacts blocks on this. Currently placeholdered as "CCO adopted by non-dissent, modifiable."
Ref: Ledger §7.2 · POV v4 §10.2
Ask: Timing for the Kristen Valdes (Founder & CEO of b.well Connected Health) consultation, sequenced post-Karen briefing. Framing locked per Brandon 2026-09-08: pursue both angles — (a) potential b.well partnership discussion (contingent on funding), (b) learn from their consent-model architecture. Not either/or.
Why: Kristen / b.well = consumer-consent model + potential H1 individual-access aggregator partnership. Complements the parallel Alya Sulaiman (Datavant GC) consultation Brandon has queued (Ledger §3.46; named 2026-09-10) — Alya provides the B2B consent-architecture / regulatory-defensibility lens, Kristen the consumer-consent lens. Both sequenced post-Karen briefing (§3.24). Second-person name-recall ask RESOLVED 2026-09-10 — was never a clinical/CMO former-Epic person; the whisper transcription mistranscribed something unrelated. Alya is Datavant GC.
Ref: Ledger §3.25 (Kristen · b.well) · §3.46 (Alya Sulaiman · Datavant GC) · §3.47 (Datavant as exploratory architecture reference)
Ask: Who in your clinical network reaches which chain at buyer level (CMO · VP Membership · Managing Partner)? This becomes the T2a sales-sequencing input. Not asking for outreach yet (Karen briefing gates that) — asking for the map so we can prioritize once cleared.
Why: T2a active direct-license segment (Friday-gated §3.42) requires warm-intro sales motion; your network is the sequencing driver. Fatima has parallel intros from Oracle Health + Salesforce H&LS + Microsoft H&LS + Allscripts + McKinsey networks — combined map gives us a real T2a pipeline.
Ref: POV v4 §6.2 + §10.2 · Chain Partnership Playbook v0.1 §1
Ask: If Karen has recommended IP counsel from her Salesforce network, or knows the shortlist for Series-A-shape startup provisional-filing counsel. $15–25K budget · 4 provisionals · target moat story includes Coverage Navigator + Advice-Boundary Classifier + Advice-Boundary Whitepaper + Plan-Delta.
Why: §3.23 IP strategy adopted by non-dissent; RFP + provisional-filing schedule owed. Publication-sequencing constraint (see POV v4 §7.5) means we cannot publish Advice-Boundary Whitepaper externally until provisionals land.
Ref: Ledger §3.23 · POV v4 §7.5
Ask: Anything new from Neko friends-and-family visit signal since 09-04? Especially: (a) confirmation Neko's user base overlaps HIFP HNW target, (b) whether they've publicly said anything about financial-planning extension. Also — your read on Aura/Oura's post-IPO strategic playbook (see POV v4 §12.7 wearable-longevity competitive threat added 09-08).
Why: §12.7 flags Aura post-IPO as most credible potential competitor at the biomarker + planning intersection. Your read on the wearable-longevity space (from Hyro-adjacent conversations + clinical network) sharpens the mitigation posture and helps prioritize the P1 Loop C wearable partnership.
Ref: Ledger §3.18 · POV v4 §12.7
Ask: 30-min sanity-check on the new POC ChartExplainer copy against the Advice-Boundary spec §3 language. Not formal review — just your read on whether the copy stays inside the boundary before we do any external demos.
Ref: Ledger §4.16
Senior health-leadership at Oracle · prospective CEO of HIFP · closes health-strategic distribution + CEO gravitas + F500 CHRO relationships
Ask: Two things: (a) your exact current Oracle title as you'd like it to appear in external materials, (b) preferred bio phrasing — one paragraph draft. Current placeholder: "Senior health-leadership at Oracle (LinkedIn stale)."
Why: Blocks team-section polish across POV v4, Investor Deck v4, Infographic v4, GC Brief, LinkedIn cues for external distribution. Currently the highest-friction gap in the team section — Sindhu's Hyro title landed 2026-09-08 (VP, Clinical Product Strategy), Brandon's title is locked, only yours is placeholdered.
Ref: Prereqs §1 · Ledger §2.1 · POV v4 §10.3
Ask: You're the one delivering the GC briefing conversation to Karen (Sindhu introduces; you carry). Please read HIFP-general-counsel-briefing-v0.1 in advance and flag anything that needs sharpening before you walk in. Specific asks for Karen embedded in the doc: standard NDA template · IP counsel referrals · risk/liability perspective · plaintiff-attorney adversarial pressure-test on §12 priced risks · Hyro employment-agreement review scope (see Sindhu ask above · POV v4 §12.8).
Why: Karen briefing is the load-bearing pre-external gate. Sequenced: Sindhu reaches out → you deliver briefing → outputs feed NDA template + IP counsel + provisional filings.
Ref: Ledger §3.24 + §3.31 · GC Briefing v0.1
Ask: Under the T1 self-funded + long-term-equity primary sub-segment (§7.14 ratified), which variants do we actively pursue vs list-and-park? Candidates: self-funded without pension · mid-market self-funded 1K–5K · government self-insurers · union benefit trusts · PEOs (Sequoia One, TriNet, Insperity) as channel · executive-health-perk sub-segment.
Why: Segment Messaging v4 §1 sub-segment matrix depends on your read. Your Oracle Health + prior Salesforce/Microsoft/Allscripts network gives the best signal on which variants have realistic warm-intro paths.
Ref: Ledger §3.34 · Friday agenda Block 3
Ask: Pressure-test the 10–20% partner rev-share range assumed for Consumer-Wellness Partnership channel deals (Function · Neko · Aura · biomarker labs). From your Oracle Health + Allscripts + McKinsey partnership experience — is that band realistic, too low, too high? Any structural terms (integration fees · minimum guarantees · exclusivity) that partners of that shape typically demand.
Why: Business Plan v4 revenue model uses this range to compute T2b unit economics + blended CAC. Getting it wrong swings the premium-case ARR by ~$5–10M. Your prior partnership experience is the highest-fidelity anchor.
Ref: GTM Tier Strategy memo §6 Q4 · POV v4 §6.3 · Ledger §3.42
Ask: Named warm-intro paths in each investor lane, by tier: Health/longevity-strategic lead lane (a16z Bio+Health · ARCH Venture · GV · Lux Capital · health-strategic vehicles) · AI-forward generalist warm-lane parallel (Sequoia AI-application · Radical Ventures · Bond · Lightspeed AI). Not asking for outreach yet — Karen gates external conversations. Asking for the map.
Why: POV v4 §5.4 + Funding Path v3 name lanes but not people. Your relationships are what turn "lead health-strategic + parallel AI-generalist" from a strategy into a sequenced outreach plan post-Karen + v4-kit.
Ref: POV v4 §5.4 + §11.1 · Alignment Pre-Read §7.7
Ask: Timeline + framing for advisor-board conversations with Michelle Feinstein and Dan Conners (NVIDIA partnerships). Both were surfaced 2026-09-07 as advisor-board candidates (Sindhu adding David / David Ventures separately). Not commitments — brainstorm-list conversations to feel out fit + interest.
Why: Advisor slots at §6.8–§6.13 + Medical Lead §6.9 are Series-A-close targets. Warm relationships take longer to convert than we sometimes assume.
Ref: Ledger §3.29 + §6.8–§6.13
Ask: The data-scientist-trained-as-actuary you mentioned as a named contact (§5.1 Ledger annotation). Timing + framing for a first conversation — advisor slot? Hiring conversation? Consultant engagement pattern? Actuary lead has been downgraded from "named" to "TBD" pending your input.
Ref: Ledger §5.1
Ask: The 2026-09-07 principle you added — HIFP's surfaced questions should mirror those a top-quartile financial planner would ask, not generic literacy prompts. If you have example questions in mind (from advisors you'd recommend to family, or from HR/wealth conversations you've had at Oracle scale) — send a handful. They anchor the corpus we'd write against.
Why: Ethical Framework Boundary-Integrity mechanic + Product Design v4 chart-explainer copy + Plan-Delta explanation copy all reference this standard. Better to anchor to real questions from real planners than to invent them.
Ref: Ledger §3.32 · POV v4 §8
Per next-meeting agenda. Trio decides; each of these has downstream artifact impact.
Decision: Ratify (or reshape) the four-lane structure I proposed 2026-09-08 — T1 Employer hyper-focus · T2a Concierge active direct-license · T2b Partner-channel D2C with Loop C primary · T3 Employer overflow leak-capture. See HIFP-gtm-tier-strategy-v0.4 for the analytical spine.
Eight open questions inside this decision:
Ref: Ledger §3.42 · GTM Tier Strategy v0.4 §7 · POV v4 §6
Decision: Current timing anchors (Ledger §7.13, informational): Brandon full-time within 4 weeks of SAFE close · Fatima pulls forward from 2027-07-01 when SAFE-covered seat funded · Sindhu April 30 2027 cliff + annually thereafter. Series A target is Q1–Q2 2027. Question for trio: does the current sequence work for what Series A DD will expect (all three founders operationally committed at close), or is there a version worth discussing where transitions are more tightly stacked around the raise?
Distinct from advisor-only fallback (Ledger §7.13 sub-part f). Fallback is "can't participate at all"; this is "how tightly do transitions cluster around the raise."
Ref: Ledger §7.13
Decision: How do we operationalize Fatima's 2026-09-07 principle — assemble small advisor-review panel (3–5 top-quartile advisors) to review + iterate HIFP's questions? Or write against a documented "top-planner questions" corpus? Or both?
Timing: Advisor-panel formation is Hustle Plan Week 1 candidate.
Ref: Ledger §3.32 · Friday agenda Block 3
Decision: Ratified Monday as open R&D, decision post-Karen. Pre-work at Friday: agree on the design constraints we're already sure of (Apple-privacy-policy standard, per-source revocation, cryptographic evidence of deletion) so Karen conversation focuses on the legal-defense-archive question specifically — not on relitigating what we already believe.
Ref: Ledger §3.27 · POV v4 §1 constraint #1
Decision: See HIFP-hustle-plan-v0.1 — my proposal to (a) reshape revenue lanes to three concurrent at MVP, (b) compress the funding-conversation feedback loop from ~10–12 wks to ~5–6 wks via parallelizing bounded-downside work. Stripe-in-MVP already locked 2026-09-07; the rest is Friday discussion.
Ref: Ledger §3.39 · Hustle Plan v0.1 · Friday agenda Block 2
Priority order I'd suggest: (1) P0 blockers first — Fatima Oracle title + Sindhu Karen-briefing timing; (2) P1 items over the next few days as they land; (3) P2 items over 2–4 weeks; (4) Joint decisions at Friday.